KalVista Pharmaceuticals to Present at Jefferies Global Healthcare Con...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: September 21, 2023

UNITE HERE Local 11: Laguna Cliffs Hospitality Workers Rally at UC Regents Meeting in Los Angeles • LeadingAge And Ziegler Release 20th Annual LeadingAge Ziegler LZ 200 Report • Revry and Discover Present The 8th Annual Queer X Awards on National Coming Out Day • Sendero Health Plans Names Sharon Alvis as Next Chief Executive • Sen. Bernie Sanders Addresses Critical Shortage of Black Physicians at the NMA's Professional Development Series • Young Travel & Cruises Educational Seminars Offer Upstate SC Travel Enthusiasts a Chance to Learn about Land, River and Sea • QuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS Antigen+ FIA • Church of the Highlands Opens New Huntsville Campus Location • COSMOSS Partners With Chopra Foundation 'Never Alone' to Support Mental Health Awareness • Métis Nation within Alberta Citizens elect new President and Citizens' Council, formally becoming the Otipemisiwak M&eacu • RazerCon 2023 Lights Up the Global Gaming Community With Groundbreaking Announcements & Exclusive Partnerships • Lieutenant General, U.S. Army (Retired) Francis M. Beaudette Named Ambassador at PenFed Foundation • Valent BioSciences Announces Construction of New Oregon Facility • Sean "Diddy" Combs Applauds Black Leaders' Commitment to Defending Democracy, Driving Corporate Diversity at Congressional Black • Mattel Publishes Latest Citizenship Report Presenting 2022 Progress on ESG Strategy and Goals • Orion S.A. Declares Interim Quarterly Dividend • Grant Funding Aims to Improve Safety & Security in New Mexico Schools • Métis Citizens elect new president in first election for new Otipemisiwak Métis Government • Five Cities Join Sunstone Economic Development Challenge @ USC Price • TinySuperheroes Celebrates Its 10th Anniversary Outfitting Courageous Kids With Superhero Capes As They Battle Illnesses and Dis

KalVista Pharmaceuticals to Present at Jefferies Global Healthcare Conference

CAMBRIDGE, Mass. & SALISBURY, England , May 31 /Businesswire/ - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will present at the Jefferies Global Healthcare Conference on Wednesday, June 7th, 2023 at 2:00 p.m. ET in New York, NY.

A live webcast of the presentation will be available on the Company’s website at www.kalvista.com. An audio archive will be available on KalVista’s website for 30 days following the presentations.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista is developing sebetralstat as an oral on-demand therapy for HAE attacks and is enrolling the Phase 3 KONFIDENT clinical trial. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE and other diseases.

For more information about KalVista, please visit www.kalvista.com.

For more information on the sebetralstat HAE on-demand Phase 3 KONFIDENT study, please visit www.konfidentstudy.com.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our Phase 3 KONFIDENT trial, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2022, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.